Gene therapy, the strategy of replacing a defective gene to treat disease, has been one of the great yet unfulfilled promises of recent years, and last month's meeting of the American Society of Gene Therapy (ASGT) in Boston was an appropriate setting to gauge the current state of the discipline.
Early in the history of the field (the mid 80s to early 90s), encouraging results in experimental systems led to genuine optimism. However, in the later 1990s enthusiasm cooled considerably as it became clear that generally poor expression of the introduced gene and possible immune complications would necessitate further fundamental research insights to achieve eventual clinical efficacy.
As interest in the field continues to grow (this year's record attendance near 2,700), it is again evident that the real potential of gene-therapy applications is tightly linked to a solid understanding of the underlying biology. This year's presentations showed that much of the careful work to optimize gene delivery, expression strategies and targeting of specific cells or tissues is progressing well. We now have better oncolytic adenoviruses, novel adeno-associated virus subtypes and improved knowledge of the tropism and dynamics of newly pseudotyped and existing lentiviral vectors. Also presented were the use of Sleeping Beauty transposase and a phage integrase to drive site-specific integration. As Malcolm Brenner put it in his Presidential Address, keeping out of the press this past year has been a positive accomplishment for the field.
The chosen theme of this year's meeting was stem cells-a timely one given recent advances and the politically charged worldwide debate over the ethics and legality of using germ-line or embryonically derived material for research and therapies. Accordingly, Irving Weissman in his keynote address outlined both clinical (transplantation of sorted hematopoietic stem cells as an alternative to whole bonemarrow transplant for cancer therapy) and basic (activation of the β-catenin pathway to enable expansion of immature stem cells in vitro) approaches that could underlie future therapies. This presentation highlighted a shifting emphasis from strict gene-based therapies to a cellbased approach.
The obvious hurdle remains getting to the clinic. The Jesse Gelsinger tragedy in 1999 halted many gene-therapy trials, and led to a further tightening of alreadystringent regulatory protocols. Academic scientists are often hobbled by a lack of familiarity with proper trial design, and the ASGT's extensive efforts at educating researchers are laudable. However, the US Food and Drug Administration (FDA), which approves novel medical therapies, is establishing a new office to consolidate all cellular, tissue and gene therapy approaches in one department, the Center for Biologics Evaluation and Research (see News, page 646), with currently unclear implications for the regulatory environment.
Gene therapy will be successful, but when? So far there is but one prominent success story, X-linked severe combined immunodeficiency, presented by Alain Fischer. French Anderson noted the many successfully completed phase 2 trials, with particular promise for DNA vaccines, conditionally replicating oncolytic viruses, angiogenesis therapies and hemophilia, and predicted FDA approval of the first gene therapy treatment within three years. Given the growth of the field and the steady flow of solid scientific results, we hope Dr. Anderson's prophecy comes to fruition.
Gene therapy-work in progress Advance Online Publication
On 3 June, Nature Medicine posted on its website the first two research articles to pass through the new Advance Online Publication (AOP) process, articles that are included in this issue (see pages 681 and page 711). With this new service, we strive to publish research articles as rapidly as possible after they have been accepted. The articles published online are the same versions that will appear in print and go through the usual rigorous process of editorial selection, peer review, editing and production. Each article is assigned a digital object identifier (DOI) number, a unique electronic identification tag that can be used for citation purposes and to retrieve the article online. Articles have an online publication date that will also appear in the print version of the article, and constitutes the formal date of publication. Articles published online are not assigned page numbers until they are part of a print issue.
We expect that two to five articles will be posted online every Monday. Authors will be notified one week before online publication that their paper has been selected for the next batch, and press embargoes will be lifted every Sunday at 2 p.m. Eastern Standard Time.
To access the online articles, subscribers can simply go to the Nature Medicine home page and click on the AOP link. There, a table of contents of papers published online lists articles in chronological order, with those posted most recently at the top. Both PDF and HTML versions of each paper are available.
For further information about AOP, please see:
http://www.nature.com/nm/aop/.
